Navigation Links
Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
Date:1/3/2008

dies further support continued development of ANA598 as a candidate for use in combination with other agents for the treatment of chronic HCV infection."

In June 2007, Anadys announced the nomination of ANA598 as a clinical development candidate. The selection of ANA598 represented the culmination of a comprehensive structure-based drug design program directed towards NS5B. ANA598 was selected based on an optimized balance of preclinical properties, including intrinsic potency as an NS5B inhibitor, cellular activity in the replicon assay, oral bioavailability and early indicators of safety and tolerability. ANA598 is a low-nanomolar inhibitor of HCV genotype 1a and 1b replicons. It exhibits good in vitro metabolic stability properties and does not significantly inhibit or induce cytochrome P450 enzymes. In vivo, ANA598 was well tolerated in 14-day dose range finding (DRF) animal toxicology studies. At doses corresponding to estimated human doses, 24 hour trough plasma concentrations of ANA598 exceeded the EC95 for HCV genotype 1a and 1b replicon inhibition. The EC95 is the concentration required in vitro to suppress hepatitis C viral RNA levels by 95% in the replicon assay.

ANA598 is currently completing IND enabling activities and an IND submission is targeted for the second quarter of 2008. "After completing the necessary IND enabling studies, we look forward to exploring the potential clinical utility of ANA598," said James Freddo, MD, Anadys' Chief Medical Officer. "Based on the in vitro and in vivo potency, pharmacokinetic and preliminary toxicologic properties of ANA598 demonstrated to date, we believe that this is an exciting new direct antiviral to investigate for the treatment of patients with hepatitis C virus infection."

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. The Company is developing ANA
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
3. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
4. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
5. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
6. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
7. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
8. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
9. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
10. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
11. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2008)... , MONTVALE, N.J., Nov. 19 /PRNewswire-First...EMY ) today announced that it has achieved the enr...54, its lead alpha-7 nicotinic receptor agonist, i...ia (CIAS). The Company has randomized 212 patient...payment from its partner Roche. Memory Pharmaceut...
(Date:11/18/2008)...gton Medical Resources (AMR), a,provider of premi...diagnostic,imaging industries, finds that over $1...he U.S. during the third quarter of 2008. Privigen...in (IVIG) and was launched in the first,quarter o...lasma of thousands,of donors and is used to treat...
(Date:11/18/2008)...d, elderly AML patients , , PRINCETON, N.J....today announced that the first patient has been tr...X-351 (Cytarabine:Daunorubicin) Liposome Injection...ukemia (AML). , , The first patient was enr...llege of Cornell University and New York Presbyte...
(Date:11/13/2008)...ut Risk of Heart Attacks, Deaths, RESTON, Va., No...sease,is the leading cause of death among American...ons of dollars and causing untold suffering. Now,t... - even among those who,weren,t thought to be at r...le could cut their risk of a,heart attack, stroke ...
Breaking Medicine Technology:Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3Over $10 Million of CSL Behring's Privigen Was Sold in the U.S. During the Third Quarter of 2008 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 3Seniors Can Be Heartened by New Study on Statins 2Baxa Corporation Launches Campaign to Recognize IV Nurse Day and Introduce the New PadLock 28R 29 Set Saver 10113 1Baxa Corporation Launches Campaign to Recognize IV Nurse Day and Introduce the New PadLock 28R 29 Set Saver 10113 2Baxa Corporation Launches Campaign to Recognize IV Nurse Day and Introduce the New PadLock 28R 29 Set Saver 10113 3DuPont Chief Science 26 Technology Officer Offers Perspectives on Science and Global Policymaking at Davos World Economic Forum 2739 1DuPont Chief Science 26 Technology Officer Offers Perspectives on Science and Global Policymaking at Davos World Economic Forum 2739 2DuPont Chief Science 26 Technology Officer Offers Perspectives on Science and Global Policymaking at Davos World Economic Forum 2739 3Oral Contraceptives Cut Ovarian Cancer Risk 10111 1Oral Contraceptives Cut Ovarian Cancer Risk 10111 2Oral Contraceptives Cut Ovarian Cancer Risk 10111 3Report 3A Too Few Physicians Nurses to Implement Presidential Candidates Health Reform Plans 10109 1Report 3A Too Few Physicians Nurses to Implement Presidential Candidates Health Reform Plans 10109 2Report 3A Too Few Physicians Nurses to Implement Presidential Candidates Health Reform Plans 10109 3
..., Tenn.--(BUSINESS WIRE)--May 25, 2007 - GTx, Inc....e recent Phase II proof of,concept clinical trial ...nical trial evaluating ACAPODENE(R) (toremifene ci...fects of androgen,deprivation therapy (ADT) will b... the American Society of Clinical Oncology being,h...
...RSBURG, Md., May 24, 2007 /PRNewswire-FirstCall/ -...nnounce results from the,Phase 1 trial of its patc...arkets open tomorrow. A conference call and live,w...rrow to discuss,the results. , Conference Call Det...May 25, 2007 at 8:30,a.m. Eastern Time via phone, ...
Other Medicine Technology:GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 2GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 3Iomai to Announce Results From Phase 1 Influenza Trial and Host,Webcast Tomorrow 2
(Date:11/21/2008)... work together to stop abusive behavior, experts s...-- Behavior that was once dismissed as "kids being...mounting research shows the negative effects on bo...ionals, schools, parents and even kids themselves ...ning behavior. , "Bullying shouldn,t be consid...
(Date:11/21/2008)...ire-FirstCall/ -- Heska Corporation,(Nasdaq: HS...rk Society of,Security Analysts, 12th Annual Biot..., 2008 at 1177 Avenue of the Americas, 2nd Floor i...begin at 9:35 a.m. Eastern Time (7:35 a.m.,Mounta...d for two weeks,following the presentation throug...
(Date:11/21/2008)...ovel technique to combat cancer, study says, ,...lgian researchers have discovered that some cancer...and this might lead to new treatments that starve ...ate, all cells in the body need to produce energy....s that requires oxygen. Compared with normal cells...
(Date:11/21/2008)...re-USNewswire/ -- U.S. News & World Report and...A) ranked BlueChoice(R) HealthPlan of South Caroli...(TM), published in U.S. News & World Report,s ...anking ranks the nation,s best health plans based ...accreditation scores. NCQA and U.S. News & Wor...
Breaking Medicine News(10 mins):Health News:Getting Tough on Bullying 2Health News:Getting Tough on Bullying 3Health News:New Approach Keeps Tumor Cells From Refueling 2Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2
...d environmental changes have caused drastic increa...ent 17% of the childhood cancer cases.// 77,111 c... 1997 in 15 European countries were analyzed in th... was an increase by an average of 1.1% a year in t...
... drug that is being developed for multiple scleros...ggests that the experimental drug fingolimod might...ultiple sclerosis. It was also reported in the stu...studies could show satisfactorily that the patient...
...nary problems than white men, but are only half as...s conducted on over 8,000 men has been published i...nternational, states that South Asian men suffer f...than white men, but are less likely to seek help. ...
...ts facing major losses to outsource medical transc...ounds a year.// Around 60 specialist posts are to ... in Leeds are reported to be facing debts of 84 mi...in Britain have already outsourced such work to In...
Other Medicine News:Health News:17 percent rise in childhood cancer cases due to modern lifestyles 2Health News:An Experimental New Drug Might Be Effective In Treating MS 2Health News:South Asian Men Have More Urinary Problems Than White Men 2Health News:Leeds Hospitals to Outsource Medical Transcription Work to India 2
Bandeau Bra
Bras and Breast Support
Compression Bra
Constructed from soft Shur-grip foam and velcro closure for easy application and - reapplication
Medicine Products: